title: [The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies].
abstract: Activated partial thromboplastin time may be prolonged as the result of either of two different autoimmune complications of chronic lymphocytic leukemia: the development of antiphospholipid antibodies, such as lupus anticoagulant or anticardiolipin antibodies, or anti-factor VIII inhibitors, such as acquired hemophilia A. In the rare simultaneous occurrence of both inhibitors, differential diagnosis of a prolonged activated partial thromboplastin time poses a number of problems during laboratory work-up, due to mutual interference of the commonly performed tests. Only careful clinical follow-up can disclose the significance of the laboratory findings. We report the case of concurrent antiphospholipid antibodies (lupus anticoagulant positivity, anticardiolipin antibodies; IgM 3880 MPL/mL and IgG 265 GPL/mL) and anti-factor VIII antibodies (46.8 Bethesda Units) in a patient with chronic B-cell lymphocytic leukemia who had prolonged activated partial thromboplastin time (78.8 s). The relationship between lymphoproliferative and antiphospholipid syndrome, laboratory work-up in the case of the association of antiphospholipid and anti-factor VIII antibodies, and related problems that occur during clinical management of the patient are also discussed.
authors.affiliation: I Divisione di Medicina Interna, Azienda Ospedaliera di Reggio Emilia.
authors.forename: A
authors.initials: A
authors.lastname: Ghirarduzzi
authors.forename: M
authors.initials: M
authors.lastname: Silingardi
authors.forename: M
authors.initials: M
authors.lastname: D'Incà
authors.forename: E
authors.initials: E
authors.lastname: Tincani
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000175:diagnosis* / Q000209:etiology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005169:Factor VIII / Q000276:immunology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D017152:Antibodies, Antiphospholipid; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005169:Factor VIII; D011241:Prednisone